GSK gets Chinese approval for shingles vaccine Shingrix

02:24 EDT 24 May 2019 | Pharmaceutical Business Review

Shingrix is a non-live and recombinant subunit adjuvanted vaccine, which will be administered intramuscularly in two doses. Shingles is caused by the reactivation of the varicella zoster virus

The post GSK gets Chinese approval for shingles vaccine Shingrix appeared first on Pharmaceutical Business review.

Original Article: GSK gets Chinese approval for shingles vaccine Shingrix

More From BioPortfolio on "GSK gets Chinese approval for shingles vaccine Shingrix"